{"ATC Code":"N06AX03","Abbreviation":"","Aliases":["Mianserine","Mianserina","Mianserinum","Tolvon","1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine","Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-","J16.389I","Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-","1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine","1,2,3,4,10,14B-hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine","5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene","5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8,10,12,15,17-hexaene","5-methyl-2,5-diazatetracyclo(13.4.0.0^(2,7).0^(8,13))nonadeca-1(15),8(13),9,11,16,18-hexaene","5-methyl-2,5-diazatetracyclo(13.4.0.0^(2,7).0^(8,13))nonadeca-1(19),8,10,12,15,17-hexaene","N06AX03","246-088-6","Mianseryna","2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine","Ncgc00015656-06","(+)-Mianserin","Cas-24219-97-4","mianserin a","Mianserin?","S(+)-Mianserin","Athymil"],"Biological Half-Life":"10-17 hours","CAS":"24219-97-4","ChEBI":"CHEBI:51137","ChEMBL":"CHEMBL6437","ChemicalClasses":["phenylpropylamine"],"Chirality":"racemic","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Second-Generation; Serotonin Antagonists","Drug Indication":"For the treatment of depression.","Drug Warnings":"Seizures were observed following the withdrawal of mianserin 60 mg/day for 2 years. To our knowledge, this is the first report of convulsions after suspension of an antidepressant. This phenomenon was observed in a young woman (with no history of epilepsy or other organic diseases that may induce seizures) 10 days after abrupt discontinuation of long-term treatment with mianserin.","EINECS":"246-088-6","Erowid Experience Reports":null,"Esters":[],"European Community (EC) Number":"246-088-6","Formating":[],"HMDB ID":"HMDB0015620","HeavyAtomCount":20,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Second-Generation; Serotonin Antagonists","IUPACName":"5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene","InChI":"InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3","InChIKey":"UEQUQVLFIPOEMF-UHFFFAOYSA-N","MeSH Pharmacological Classification":"A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)","MolecularFormula":"C\u003csub\u003e18\u003c/sub\u003eH\u003csub\u003e20\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"264.4 g/mol","Pharmacodynamics":"Mianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems.","Physical Description":"Solid","PubChemId":4184,"RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Mianserin","Name":"Mianserin","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB06148","Name":"Mianserin","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4184","Name":"Mianserin","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/154315","Name":"(S)-Mianserin","Sub":true},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/154412","Name":"(R)-Mianserin","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL6437","Name":"Mianserin","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL252719","Name":"(S)-Mianserin","Sub":true},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1329927","Name":"(R)-Mianserin","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51137","Name":"Mianserin","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=24219-97-4","Name":"Mianserin","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=51152-88-6","Name":"(S)-Mianserin","Sub":true},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=78684-63-6","Name":"(R)-Mianserin","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015620","Name":"Mianserin","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D08216","Name":"Mianserin","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/250PJI13LM","Name":"Mianserin","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/A1AD8U189I","Name":"(S)-Mianserin","Sub":true},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/83SJB1688K","Name":"(R)-Mianserin","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6023317","Name":"Mianserin","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID50199175","Name":"(S)-Mianserin","Sub":true},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID601017357","Name":"(R)-Mianserin","Sub":true}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4184, Mianserin. Accessed July 21, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/4184\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/4184\u003c/a\u003e"],"SMILES":"CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42","SaltData":[],"Salts":[],"Solubility":"2.32e-01 g/L","StereoisomerData":[{"Aliases":["(S)-mianserin","Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (14bS)-","Mianserin, (S)-","Lerivon","N-(Carboxymethyl)amphetamine","(S)-(+)-Mianserin","N-(a-Methylphenethyl)glycine Hydrochloride;","Mianserin","Mianserin, (+)-","Pdsp1_001433","Pdsp2_001417","(S)-1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine","(S)-1,2,3.4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine","(S)-(+)-Mianserin; Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (14bS)-; Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (S)-; (14bS)-1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; (+)-(S)-Mianserin; (","WRU"],"PubChemId":154315,"SMILES":"CN1CCN2[C@H](C1)C3=CC=CC=C3CC4=CC=CC=C42","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 85.653 85.793\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h86v86H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m40.763 84.795 3.319-10.777M48.555 69.474l11.551-2.641M60.106 66.833l4.485-14.565M64.591 52.268l-7.477-8.051M39.365 44.498l11.55-2.641M39.365 44.498l-4.486 14.565M42.356 67.115l-7.477-8.052M39.365 44.498l-11.921-9.494\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 42.624 13.198-7.62M14.247 39.808l10.758-6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"M14.246 42.624 1.043 34.995\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 19.747.005 15.248M3.477 21.154l.004 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.038 19.747 13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.439 19.755-13.203-7.628M25.002 21.163l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.444 35.004-.005-15.249M27.439 19.755l11.915-9.502M39.354 10.253l14.857 3.388\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m62.792 1.046-8.581 12.595M64.015 3.583l-6.996 10.268\"/\u003e\u003c/g\u003e\u003cpath d=\"M62.792 1.046 77.99 2.181\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M84.607 15.91 77.99 2.181M81.799 15.7 76.405 4.508\"/\u003e\u003c/g\u003e\u003cpath d=\"m84.607 15.91-8.582 12.594\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m60.827 27.369 15.198 1.135M62.413 25.042l12.39.926\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.211 13.641 6.616 13.728M56.006 37.39l4.821-10.021\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M47.19 72.68h-.721l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578zM56.161 43.551h-.72l-2.62-4.066h-.029l.029.595q.024.357.024.732v2.739h-.565v-4.9h.714l2.607 4.054h.03l-.018-.327-.024-.476q-.005-.262-.005-.483v-2.768h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m44.082 74.018-1.66 5.388M48.555 69.474l5.776-1.32M57.114 44.217l3.738 4.025M50.915 41.857l-5.775 1.32M42.356 67.115l-3.739-4.026M56.006 37.39l2.41-5.01\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"(S)-Mianserin","UNII":"A1AD8U189I"},{"Aliases":["(R)-mianserin","Mianserin, (R)-","(R)-(+)-Mianserin","Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (14bR)-","Tocris-0997","Lopac-M-2525","Mianserin, (-)-","Pdsp1_001434","Pdsp2_001418","Mrf-0000741","Ncgc00015656-01","Ncgc00015656-02","Ncgc00015656-03","Ncgc00015656-07","Ncgc00016753-01","Ncgc00024926-01","Cas-21535-47-7","Q27895530","(R)-(+)-Mianserin; Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (14bR)-; Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (R)-; (14bR)-1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; (-)-(R)-Mianserin; ("],"PubChemId":154412,"SMILES":"CN1CCN2[C@@H](C1)C3=CC=CC=C3CC4=CC=CC=C42","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 85.653 85.793\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h86v86H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m40.763 84.795 3.319-10.777M48.555 69.474l11.551-2.641M60.106 66.833l4.485-14.565M64.591 52.268l-7.477-8.051M39.365 44.498l11.55-2.641M39.365 44.498l-4.486 14.565M42.356 67.115l-7.477-8.052M39.365 44.498l-11.921-9.494\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 42.624 13.198-7.62M14.247 39.808l10.758-6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"M14.246 42.624 1.043 34.995\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 19.747.005 15.248M3.477 21.154l.004 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.038 19.747 13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.439 19.755-13.203-7.628M25.002 21.163l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.444 35.004-.005-15.249M27.439 19.755l11.915-9.502M39.354 10.253l14.857 3.388\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m62.792 1.046-8.581 12.595M64.015 3.583l-6.996 10.268\"/\u003e\u003c/g\u003e\u003cpath d=\"M62.792 1.046 77.99 2.181\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M84.607 15.91 77.99 2.181M81.799 15.7 76.405 4.508\"/\u003e\u003c/g\u003e\u003cpath d=\"m84.607 15.91-8.582 12.594\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m60.827 27.369 15.198 1.135M62.413 25.042l12.39.926\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.211 13.641 6.616 13.728M56.006 37.39l4.821-10.021\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M47.19 72.68h-.721l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578zM56.161 43.551h-.72l-2.62-4.066h-.029l.029.595q.024.357.024.732v2.739h-.565v-4.9h.714l2.607 4.054h.03l-.018-.327-.024-.476q-.005-.262-.005-.483v-2.768h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m44.082 74.018-1.66 5.388M48.555 69.474l5.776-1.32M57.114 44.217l3.738 4.025M50.915 41.857l-5.775 1.32M42.356 67.115l-3.739-4.026M56.006 37.39l2.41-5.01\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"(R)-Mianserin","UNII":"83SJB1688K"}],"StereoisomerType":"enantiomer","Stereoisomers":["(S)-Mianserin","(R)-Mianserin"],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 85.653 85.793\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h86v86H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m40.763 84.795 3.319-10.777M48.555 69.474l11.551-2.641M60.106 66.833l4.485-14.565M64.591 52.268l-7.477-8.051M50.915 41.857l-11.55 2.641M39.365 44.498l-4.486 14.565M42.356 67.115l-7.477-8.052M39.365 44.498l-11.921-9.494\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 42.624 13.198-7.62M14.247 39.808l10.758-6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"M14.246 42.624 1.043 34.995\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 19.747.005 15.248M3.477 21.154l.004 12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.038 19.747 13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.439 19.755-13.203-7.628M25.002 21.163l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.444 35.004-.005-15.249M27.439 19.755l11.915-9.502M39.354 10.253l14.857 3.388\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m62.792 1.046-8.581 12.595M64.015 3.583l-6.996 10.268\"/\u003e\u003c/g\u003e\u003cpath d=\"M62.792 1.046 77.99 2.181\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M84.607 15.91 77.99 2.181M81.799 15.7 76.405 4.508\"/\u003e\u003c/g\u003e\u003cpath d=\"m84.607 15.91-8.582 12.594\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m60.827 27.369 15.198 1.135M62.413 25.042l12.39.926\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.211 13.641 6.616 13.728M56.006 37.39l4.821-10.021\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M47.19 72.68h-.721l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578zM56.161 43.551h-.72l-2.62-4.066h-.029l.029.595q.024.357.024.732v2.739h-.565v-4.9h.714l2.607 4.054h.03l-.018-.327-.024-.476q-.005-.262-.005-.483v-2.768h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m44.082 74.018-1.66 5.388M48.555 69.474l5.776-1.32M57.114 44.217l3.738 4.025M50.915 41.857l-5.775 1.32M42.356 67.115l-3.739-4.026M56.006 37.39l2.41-5.01\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"EXPTL Therapy: 114 patients with chronic tension headache (more than 10 days per month for at least 6 months) were treated with placebo, clomipramine or mianserin in a double blind parallel group comparison. Eighty-two patients completed the study. Headache pain was scored weekly on visual analogue scales for the 6 weeks of treatment. Observer-rating of headache was made at entry, after 3 weeks and after 6 weeks of treatment. In all groups, headache complaints decreased significantly compared to baseline. With the main parameter the decrease on both clomipramine and mianserin was significant compared to placebo. Although the trend was the same for the other parameters, the changes relative to placebo did not reach statistical significance.","Title":"Mianserin","UNII":"250PJI13LM","Wikipedia":"Mianserin","XLogP":3.4}